Retrophin, Inc. (RTRX)


Stock Price Forecast

Nov. 18, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Retrophin, Inc. chart...

About the Company

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Sector

Health Technology

Industry

Biotechnology

Employees

221

CEO

Eric Dube

Exchange

NASDAQ

Website

http://www.retrophin.com

$194M

Total Revenue

221

Employees

$1B

Market Capitalization

-14.02

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RTRX News

Retrophin to Present at 25th Annual ROTH Conference

11y ago, source: AOL

NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases ...

KaloBios Plunges 50 Percent After CEO Martin Shkrelis Arrest

8y ago, source: Traders Magazine

Prosecutors have charged Shkreli with illegally taking stock from Retrophin Inc., a biotechnology firm he started in 2011, and using it pay off debts from unrelated business dealings. (Bloomberg) — ...

Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21d ago, source: ADVFN

Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 58,750 ...

US sells Wu-Tang album to settle ‘Pharma Bro’ Shkreli’s court debt

2y ago, source: Courthouse News Service

Shkreli was the founder and managing member of hedge funds MSMB Capital Management and MSMB Healthcare Management, and the CEO of biopharmaceutical company Retrophin Inc. A jury found Shkreli guilty ...

Buy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlook

15d ago, source: Business Insider

Begin your TipRanks Premium journey today. Travere Therapeutics (TVTX) Company Description: Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development ...

Sweet Baby Inc. Doesn’t Do What Some Gamers Think It Does

22d ago, source: Kotaku

Sweet Baby Inc. is not the largest narrative design company in the games industry. Nor is it solely responsible for the characters and stories in recent high-profile releases like Alan Wake 2 ...

Welcome to Inc.'s Directory of B2B Excellence

5mon ago, source: Inc

They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.

Snap Inc Class A

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

STIHL Inc.

7mon ago, source: Forbes

This company has paid to receive expanded profile features. About STIHL Inc. Virginia-based STIHL Inc. is the U.S. affiliate for the global STIHL group and the manufacturer of the number one ...

Beasley Broadcast Group, Inc. (BBGI)

3d ago, source: Yahoo Finance

Beasley Broadcast Group, Inc. ( NASDAQ:BBGI ) shareholders are probably feeling a little disappointed, since its shares... Simply Wall St. Beasley Broadcast Group Full Year 2023 Earnings ...

Apple Inc.

11mon ago, source: Wall Street Journal

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Snap Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...